{"id":"afp-specific-t-cell-receptor-t-cells","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1697734","moleculeType":"Small molecule","molecularWeight":"227.65"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AFP Specific T Cell Receptor T Cells are a type of immunotherapy that uses genetically modified T cells to recognize and attack cancer cells expressing the alpha-fetoprotein (AFP) antigen.","oneSentence":"Specific T Cell Receptor T Cells target the AFP antigen","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:51:16.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of AFP-positive cancers"}]},"trialDetails":[{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT06515314","phase":"PHASE1","title":"HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Ruiliyuan Biotechnology Co., Ltd.","startDate":"2024-10-17","conditions":"Hepatic Cell Carcinoma","enrollment":12},{"nctId":"NCT03132792","phase":"PHASE1","title":"AFPᶜ³³²T in Advanced HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Adaptimmune","startDate":"2017-05-08","conditions":"Hepatocellular Cancer, AFP Expressing Tumors","enrollment":45},{"nctId":"NCT04368182","phase":"PHASE1","title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2020-04-13","conditions":"Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT03971747","phase":"PHASE1","title":"AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai AbelZeta Ltd.","startDate":"2019-08-06","conditions":"Hepatocellular Carcinoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AFP Specific T Cell Receptor T Cells","genericName":"AFP Specific T Cell Receptor T Cells","companyName":"Shanghai Ruiliyuan Biotechnology Co., Ltd.","companyId":"shanghai-ruiliyuan-biotechnology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Specific T Cell Receptor T Cells target the AFP antigen Used for Treatment of AFP-positive cancers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}